MARKET WIREReuters • 3h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why CYRX Stock slipped -1.88% Today — RQD Quant Desk Flash
$18.29 -1.88% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $18.19
CryoPort Inc. (CYRX) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $926.4M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $18.19 (-0.53%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CYRX)Realized 20D OHLCV Swing Band: ±9.3%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY CYRX SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+10/20 pts (26% of score)
20D Institutional Volume Accumulation (±9.3% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (26% of score)
Altman Z-Score 1.33 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9
▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)
Capital intensity & 0% operating margin leave 16 pts on the table
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$17.35-2.9% Next Q
30
Q2 (-2Q)Grade E$16.84+6.8% Next Q
33
Q3 (-1Q)Grade E$17.98+1.7% Next Q
35
CurrentGrade D-$18.29-7.8% Hist 90D α
38
Trajectory: E (30) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CYRX Turnaround Squeeze
While CYRX currently carries a cautious 38/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($16.96) and Max Pain ($19.20) forces dealer call-delta covering toward $19.82.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CYRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CYRX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CYRX Stock slipped -1.88% Today — RQD Quant Desk Flash
CryoPort Inc. (CYRX) slipped -1.88% to $18.29, trading at 95% of its 52-week range ($7.61 – $18.88). Stretched risk/reward at 12x P/E (-12% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 95% of its 52-week range ($7.61 – $18.88) with RSI-14 at 48.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±9.3% around $18.29 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 47.1% gross margin and $0 annual free cash flow.
Live CYRX Headlines & Catalysts
MARKET WIRECNBC • 5h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 5h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 7h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 8h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 9h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 9h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 10h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CYRX)
- ✓Walkthrough of CYRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CYRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +78.27%⚡ TESTING RESISTANCE
2026-10-30O $17.94H $18.29L $17.14C $18.29VOL 1.04M
RES: $18.95SUP: $14.37SMA50: $16.96SMA200: $13.30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CYRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
2.2%/yr Implied 5Y Growth
vs. +12.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CYRX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CYRX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CYRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CYRX)
Health Care Rank #701 of 1016
⚔️ ANRO vs CYRX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CYRX vs. ANRO, ORIC, AKTS, KURA)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, CryoPort Inc. (CYRX) ranks #701 by composite RQD confidence (38/100, grade D-) and #373 by equity capitalization ($926.4M). Within this direct 5-issuer industry benchmark cohort, CYRX leads on earnings valuation at 11.8x trailing P/E, while CYRX leads on capital efficiency and profitability with -11.5% ROIC and 47.1% gross margin. AKTS currently holds the highest overall quantitative score in the immediate peer group at 56/100 (D+) compared with CYRX at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CYRX
ACTIVE
CryoPort Inc. | D- | 38/100 | 11.8x | 47.1% | -11.5% | -1.88% | $926.4M | Benchmark Subject |
| ANRO Alto Neuroscience Inc. | D- | 38/100 | — | — | -35.0% | +0.60% | $921.0M | /anro-vs-cyrx → |
| ORIC Oric Pharmaceuticals Inc. | D- | 39/100 | — | — | -33.4% | -3.33% | $931.8M | /oric-vs-cyrx → |
| AKTS Aktis Oncology Inc. | D+ | 56/100 | — | — | — | +0.18% | $937.2M | /akts-vs-cyrx → |
| KURA Kura Oncology Inc. | E | 29/100 | — | — | -35.0% | -1.49% | $939.4M | /kura-vs-cyrx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001124524In its most recent audited fiscal period (FY2025, filed 2025-12-31), CryoPort Inc. (CYRX) reported GAAP revenue of $176.2M (+12.4% vs. FY2024 revenue of $156.8M , and +4.5% cumulative change since FY2023) , GAAP net income of $78.3M, operating cash flow of -$8.6M, and free cash flow of -$25.0M (+25.5% YoY). On the balance sheet, CYRX closed FY2025 with $765.0M in total assets against $0 in total debt (Altman Z-Score: 1.33, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $176.2M | $78.3M | -$8.6M | -$25.0M | $765.0M | — |
| FY2024 (FY) | 2024-12-31 | $156.8M | -$114.8M | -$16.3M | -$33.6M | $703.5M | — |
| FY2023 (FY) | 2023-12-31 | $168.7M | -$99.6M | -$757.0K | -$757.0K | — | — |
3. CYRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CYRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, CryoPort Inc. (NASDAQ: CYRX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $18.29 (-1.88% 1D, market cap $926.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, CYRX ranks #701 in composite RQD confidence.
How does CYRX compare to ANRO and ORIC in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CYRX carries a Roarable D- (38/100 RQD), trailing P/E of 11.8x, gross margin of 47.1%, and ROIC of -11.5%. By comparison, ANRO (Alto Neuroscience Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $921.0M) and ORIC (Oric Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -33.4%, cap $931.8M). Among the 5-stock peer group, CYRX leads on earnings multiple (11.8x) while CYRX leads on capital efficiency (-11.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CYRX?
Per CYRX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001124524), CryoPort Inc. generated $176.2M in revenue (+12.4% YoY), $78.3M in net income, and -$25.0M in free cash flow against $765.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CYRX trading relative to its 50-day, 200-day, and 52-week technical levels?
CYRX last traded at $18.29 (-1.88% on volume of 2,228,204 shares), positioning the stock +7.84% above its 50-day simple moving average ($16.96) and +37.52% above its 200-day simple moving average ($13.30). Across its 52-week range of $7.61 to $18.88, CYRX sits at the 94.8% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±9.3% ($16.59 to $19.99).
CYRX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CYRX stock moving today?
Why CYRX Stock slipped -1.88% Today — RQD Quant Desk Flash. Stretched risk/reward at 12x P/E (-12% return on capital) under elevated 10-year interest-rate pressure.